These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 372846)

  • 1. [Experiments with a new drug in chronic liver diseases, especially alcohol-induced].
    Bel A; Chambon A
    Minerva Dietol Gastroenterol; 1977; 23(3):243-8. PubMed ID: 372846
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 3. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1984; 19(1):23-9. PubMed ID: 6149758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palmitoyl-catechin for alcoholic liver disease: results of a three-month clinical trial.
    World MJ; Ryle PR; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1987; 22(4):331-40. PubMed ID: 3322310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L; Dávid K; Nagy I; Stotz G; Kelemen JT
    Acta Physiol Hung; 1984; 64(3-4):461-70. PubMed ID: 6152370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of therapy in chronic liver diseases. Double-blind study with cianidanol].
    Machalke K; Müller B
    Fortschr Med; 1982 Apr; 100(14):665-7. PubMed ID: 6123478
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A double-blind clinical study of the effect of a new molecule (+)-cyanidanol-3 on the course of the clinical symptoms and biological parameters of viral hepatitis].
    Cachin M; Dupuy R; Boutelier D; Levy C
    Minerva Dietol Gastroenterol; 1977; 23(4):307-12. PubMed ID: 349422
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of chronic hepatitis. A comparative study of the effect azathioprine and (+)-cyanidanol-3].
    Aguilar Reina J; de la Santa López J; Cuadras Avellana CM; Kern A
    Fortschr Med; 1978 Jan; 96(2):75-9. PubMed ID: 74352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G; Salamon F
    Acta Physiol Hung; 1984; 64(3-4):443-8. PubMed ID: 6152368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled clinical trial in the treatment of chronic hepatopathy of toxico-metabolic etiology].
    Carrara G; Fiocchi G; Sotti A; Dieci MG; Fiorani F; Galvani V
    Clin Ter; 1984 Jun; 109(6):545-55. PubMed ID: 6236945
    [No Abstract]   [Full Text] [Related]  

  • 13. [Influence of (+)-cyanidanol-3 on the course of acute viral hepatitis (author's transl)].
    Vido I; Schmidt FW; Müller R; Ranft U; Wildhirt E; Holzer E; Wallnöfer H; Korb G
    Dtsch Med Wochenschr; 1980 Mar; 105(10):330-2. PubMed ID: 6153953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomised double-blind trial.
    Colman JC; Morgan MY; Scheuer PJ; Sherlock S
    Gut; 1980 Nov; 21(11):965-9. PubMed ID: 6108901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G
    Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease.
    Orrego H; Kalant H; Israel Y; Blake J; Medline A; Rankin JG; Armstrong A; Kapur B
    Gastroenterology; 1979 Jan; 76(1):105-15. PubMed ID: 758131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of (+)-cyanidanol-3 on receptor activity of lymphocytes and hepatocytes and on hepatocyte-lymphocyte conjugation in alcoholic liver disease.
    Sipos J; Gabor V; Toth Z; Ribiczey P
    Int J Tissue React; 1984; 6(2):145-54. PubMed ID: 6203861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enzymologic evaluation of the effectiveness of the hepatotropic drug catergen in chronic liver diseases].
    Tamarkina AD; Neverov IV; Turitsyna IG; Dement'eva ES; Krylova NI
    Sov Med; 1985; (12):26-30. PubMed ID: 4095626
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical study of the effect of the administration of cathergen preparation in patients with chronic hepatic lesions].
    Maleev A; Tsvetkova V; Krŭstev Z; Kostova N; Lukanov L
    Vutr Boles; 1985; 24(5):39-43. PubMed ID: 4090451
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of (+)-cyanidanol-3 in the treatment of chronic active hepatitis (author's transl)].
    Demeulenaere F; Desmet VJ; Dupont E; Fiasse R; Gisselbrecht H; Heully F; Jeanpierre R; Lecomte J; Lennes G; Macinot C; Migeotte P; Pirotte J; Rauber G; Ruyters L; Van Cauwenberge H
    Gastroenterol Clin Biol; 1981 Mar; 5(3):314-23. PubMed ID: 7014344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.